A Randomized, Double-Blind, Double-Dummy, Parallel Fluconazole Controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis (RVVC)
Latest Information Update: 05 Oct 2023
At a glance
- Drugs Oteseconazole (Primary) ; Fluconazole
- Indications Vulvovaginal candidiasis
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 03 Nov 2021 According to a Mycovia Pharmaceuticals media release, The first subject was enrolled in September 2021, and enrollment is expected to complete in Q3 2022.
- 13 Oct 2021 New trial record
- 29 Sep 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last Verified September 2021).